Alpha-1 Antitrypsin Deficiency Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Dicerna Initiates Patient Dosing in ESTRELLA Phase 2 Clinical Trial of Belcesiran for the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
LEXINGTON, Mass.--(BUSINESS WIRE) June 22, 2021 -- Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the“Company” or“Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, announced... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - June 22, 2021 Category: Pharmaceuticals Source Type: clinical trials

A randomised, double-blind, placebo-controlled, pilot trial of intravenous plasma purified alpha-1 antitrypsin for SARS-CoV-2-induced Acute Respiratory Distress Syndrome: a structured summary of a study protocol for a randomised, controlled trial
AbstractObjectivesThe primary objective is to demonstrate that, in patients with PCR-confirmed SARS-CoV-2 resulting in Acute Respiratory Distress Syndrome (ARDS), administration of 120mg/kg of body weight of intravenous Prolastin ®(plasma-purified alpha-1 antitrypsin) reduces circulating plasma levels of interleukin-6 (IL-6). Secondary objectives are to determine the effects of intravenous Prolastin® on important clinical outcomes including the incidence of adverse events (AEs) and serious adverse events (SAEs).Trial designPhase 2, randomised, double-blind, placebo-controlled, pilot trial.ParticipantsThe study will be co...
Source: Trials - April 19, 2021 Category: Research Source Type: clinical trials

Alpha-1-Antitrypsin-Deficiency in COVID-19
Condition: Covid19 Intervention: Drug: AAT( Alpha 1 Antitrypsin) Sponsor: Universität des Saarlandes Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 16, 2021 Category: Research Source Type: clinical trials